|
Leader
|
|
|
00000nz a2200037n 45 0 |
|
001
|
|
|
WKP|Q81578725
(VIAF cluster)
(Authority/Source Record)
|
|
003
|
|
|
WKP |
|
005
|
|
|
20241221010733.0 |
|
008
|
|
|
241221nneanz||abbn n and d |
|
035
|
|
|
‡a
(WKP)Q81578725
|
|
024
|
|
|
‡a
0000-0001-7293-2278
‡2
orcid
|
|
024
|
|
|
‡a
11939768100
‡2
scopus
|
|
035
|
|
|
‡a
(OCoLC)Q81578725
|
|
100
|
0 |
|
‡a
Diego F Hernández-Ramírez
‡c
researcher
‡9
en
|
|
400
|
0 |
|
‡a
Diego F Hernández-Ramírez
‡c
wetenschapper
‡9
nl
|
|
670
|
|
|
‡a
Author's Autoimmune comorbidity in achalasia patients
|
|
670
|
|
|
‡a
Author's Cellular immune response to β2-glycoprotein-I valine/leucine247 phenotypes in Mexican patients with primary antiphospholipid syndrome.
|
|
670
|
|
|
‡a
Author's Characterization of monoclonal anti-beta2-glycoprotein-I and anti-prothrombin antibody fragments generated by phage display from a patient with primary antiphospholipid syndrome.
|
|
670
|
|
|
‡a
Author's Chemokine saliva levels in patients with primary Sjögren's syndrome, associated Sjögren's syndrome, pre-clinical Sjögren's syndrome and systemic autoimmune diseases
|
|
670
|
|
|
‡a
Author's [Citrullinated proteins in rheumatoid arthritis]
|
|
670
|
|
|
‡a
Author's Correction: The Role of High Mobility Group Box 1 Protein
|
|
670
|
|
|
‡a
Author's Correction: The Role of High Mobility Group Box 1 Protein (HMGB1) in the Immunopathology of Experimental Pulmonary Tuberculosis.
|
|
670
|
|
|
‡a
Author's Elastographic ultrasound: an additional image tool in Sjögren's syndrome
|
|
670
|
|
|
‡a
Author's Endothelial progenitor dysfunction associates with a type I interferon signature in primary antiphospholipid syndrome
|
|
670
|
|
|
‡a
Author's [Immunological Techniques that Support the Diagnosis of the Autoimmune Diseases]
|
|
670
|
|
|
‡a
Author's Potential additional effect of omentectomy on metabolic syndrome, acute-phase reactants, and inflammatory mediators in grade III obese patients undergoing laparoscopic Roux-en-Y gastric bypass: a randomized trial
|
|
670
|
|
|
‡a
Author's Prevalence and associations of anti-phosphatidylserine/prothrombin antibodies with clinical phenotypes in patients with primary antiphospholipid syndrome: aPS/PT antibodies in primary antiphospholipid syndrome
|
|
670
|
|
|
‡a
Author's Refractory ascites in systemic lupus erythematosus: further biological support of intraperitoneal steroid treatment as a suitable therapeutical option.
|
|
670
|
|
|
‡a
Author's Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: a newly identified mechanism of thrombosis in the antiphospholipid syndrome.
|
|
670
|
|
|
‡a
Author's The amount of citrullinated proteins in synovial tissue is related to serum anti-cyclic citrullinated peptide (anti-CCP) antibody levels
|
|
670
|
|
|
‡a
Author's The Role of High Mobility Group Box 1 Protein (HMGB1) in the Immunopathology of Experimental Pulmonary Tuberculosis.
|
|
670
|
|
|
‡a
Author's The role of β2-glycoprotein I (β2GPI) carbohydrate chains in the reactivity of anti-β2GPI antibodies from patients with primary antiphospholipid syndrome and in the activation and differentiation of U937 cells
|
|
909
|
|
|
‡a
(orcid) 0000000172932278
‡9
1
|
|
909
|
|
|
‡a
(scopus) 11939768100
‡9
1
|
|
919
|
|
|
‡a
autoimmunecomorbidityinachalasiapatients
‡A
Autoimmune comorbidity in achalasia patients
‡9
1
|
|
919
|
|
|
‡a
prevalenceandassociationsofantiphosphatidylserineprothrombinantibodieswithclinicalphenotypesinpatientswithprimaryantiphospholipidsyndromeapsptantibodiesinprimaryantiphospholipidsyndrome
‡A
Prevalence and associations of anti-phosphatidylserine/prothrombin antibodies with clinical phenotypes in patients with primary antiphospholipid syndrome: aPS/PT antibodies in primary antiphospholipid syndrome
‡9
1
|
|
919
|
|
|
‡a
refractoryascitesinsystemiclupuserythematosusfurtherbiologicalsupportofintraperitonealsteroidtreatmentasasuitabletherapeuticaloption
‡A
Refractory ascites in systemic lupus erythematosus: further biological support of intraperitoneal steroid treatment as a suitable therapeutical option.
‡9
1
|
|
919
|
|
|
‡a
releaseofneutrophilextracellulartrapsbyneutrophilsstimulatedwithantiphospholipidantibodiesanewlyidentifiedmechanismofthrombosisintheantiphospholipidsyndrome
‡A
Release of neutrophil extracellular traps by neutrophils stimulated with antiphospholipid antibodies: a newly identified mechanism of thrombosis in the antiphospholipid syndrome.
‡9
1
|
|
919
|
|
|
‡a
amountofcitrullinatedproteinsinsynovialtissueisrelatedtoserumanticycliccitrullinatedpeptideanticcpantibodylevels
‡A
The amount of citrullinated proteins in synovial tissue is related to serum anti-cyclic citrullinated peptide (anti-CCP) antibody levels
‡9
1
|
|
919
|
|
|
‡a
roleofhighmobilitygroupbox1proteinhmgb1intheimmunopathologyofexperimentalpulmonarytuberculosis
‡A
The Role of High Mobility Group Box 1 Protein (HMGB1) in the Immunopathology of Experimental Pulmonary Tuberculosis.
‡9
1
|
|
919
|
|
|
‡a
roleofβ2glycoprotein1β2gpicarbohydratechainsinthereactivityofantiβ2gpiantibodiesfrompatientswithprimaryantiphospholipidsyndromeandintheactivationanddifferentiationofu937cells
‡A
The role of β2-glycoprotein I (β2GPI) carbohydrate chains in the reactivity of anti-β2GPI antibodies from patients with primary antiphospholipid syndrome and in the activation and differentiation of U937 cells
‡9
1
|
|
919
|
|
|
‡a
cellularimmuneresponsetoβ2glycoprotein1valineleucine247phenotypesinmexicanpatientswithprimaryantiphospholipidsyndrome
‡A
Cellular immune response to β2-glycoprotein-I valine/leucine247 phenotypes in Mexican patients with primary antiphospholipid syndrome.
‡9
1
|
|
919
|
|
|
‡a
characterizationofmonoclonalantibeta2glycoprotein1andantiprothrombinantibodyfragmentsgeneratedbyphagedisplayfromapatientwithprimaryantiphospholipidsyndrome
‡A
Characterization of monoclonal anti-beta2-glycoprotein-I and anti-prothrombin antibody fragments generated by phage display from a patient with primary antiphospholipid syndrome.
‡9
1
|
|
919
|
|
|
‡a
chemokinesalivalevelsinpatientswithprimarysjogrenssyndromeassociatedsjogrenssyndromepreclinicalsjogrenssyndromeandsystemicautoimmunediseases
‡A
Chemokine saliva levels in patients with primary Sjögren's syndrome, associated Sjögren's syndrome, pre-clinical Sjögren's syndrome and systemic autoimmune diseases
‡9
1
|
|
919
|
|
|
‡a
citrullinatedproteinsinrheumatoidarthritis
‡A
[Citrullinated proteins in rheumatoid arthritis]
‡9
1
|
|
919
|
|
|
‡a
correctiontheroleofhighmobilitygroupbox1protein
‡A
Correction: The Role of High Mobility Group Box 1 Protein
‡9
1
|
|
919
|
|
|
‡a
correctiontheroleofhighmobilitygroupbox1proteinhmgb1intheimmunopathologyofexperimentalpulmonarytuberculosis
‡A
Correction: The Role of High Mobility Group Box 1 Protein (HMGB1) in the Immunopathology of Experimental Pulmonary Tuberculosis.
‡9
1
|
|
919
|
|
|
‡a
elastographicultrasoundanadditionalimagetoolinsjogrenssyndrome
‡A
Elastographic ultrasound: an additional image tool in Sjögren's syndrome
‡9
1
|
|
919
|
|
|
‡a
endothelialprogenitordysfunctionassociateswithatype1interferonsignatureinprimaryantiphospholipidsyndrome
‡A
Endothelial progenitor dysfunction associates with a type I interferon signature in primary antiphospholipid syndrome
‡9
1
|
|
919
|
|
|
‡a
immunologicaltechniquesthatsupportthediagnosisoftheautoimmunediseases
‡A
[Immunological Techniques that Support the Diagnosis of the Autoimmune Diseases]
‡9
1
|
|
919
|
|
|
‡a
potentialadditionaleffectofomentectomyonmetabolicsyndromeacutephasereactantsandinflammatorymediatorsingrade3obesepatientsundergoinglaparoscopicrouxenygastricbypassarandomizedtrial
‡A
Potential additional effect of omentectomy on metabolic syndrome, acute-phase reactants, and inflammatory mediators in grade III obese patients undergoing laparoscopic Roux-en-Y gastric bypass: a randomized trial
‡9
1
|
|
996
|
|
|
‡2
DNB|131842641
|
|
996
|
|
|
‡2
BNCHL|10000000000000000125419
|
|
996
|
|
|
‡2
ARBABN|000034674
|
|
996
|
|
|
‡2
LC|no2011155971
|
|
996
|
|
|
‡2
ISNI|0000000060265124
|
|
996
|
|
|
‡2
ISNI|0000000062687099
|
|
996
|
|
|
‡2
BNCHL|10000000000000000188905
|
|
996
|
|
|
‡2
DNB|1209705850
|
|
996
|
|
|
‡2
BNCHL|10000000000000000098945
|
|
996
|
|
|
‡2
LC|nb2009025278
|
|
996
|
|
|
‡2
BNCHL|10000000000000000807360
|
|
996
|
|
|
‡2
BNE|XX1447903
|
|
996
|
|
|
‡2
J9U|987012281244605171
|
|
996
|
|
|
‡2
LC|ns2016001821
|
|
996
|
|
|
‡2
LC|no2023060309
|
|
996
|
|
|
‡2
SUDOC|16914383X
|
|
996
|
|
|
‡2
BNE|XX5716143
|
|
996
|
|
|
‡2
LC|no2022107115
|
|
996
|
|
|
‡2
LC|no2006060347
|
|
996
|
|
|
‡2
NTA|231582994
|
|
996
|
|
|
‡2
LC|ns2024002842
|
|
996
|
|
|
‡2
BNE|XX1776071
|
|
996
|
|
|
‡2
SUDOC|265469244
|
|
996
|
|
|
‡2
PTBNP|122627
|
|
996
|
|
|
‡2
LC|no 99092329
|
|
996
|
|
|
‡2
ISNI|0000000356391859
|
|
996
|
|
|
‡2
SUDOC|280236271
|
|
996
|
|
|
‡2
BNE|XX1026772
|
|
996
|
|
|
‡2
BNE|XX5470258
|
|
996
|
|
|
‡2
BNC|981058523470406706
|
|
996
|
|
|
‡2
LC|no2022140880
|
|
996
|
|
|
‡2
LC|ns2022001274
|
|
996
|
|
|
‡2
ISNI|0000000059267448
|
|
996
|
|
|
‡2
BNE|XX1088876
|
|
996
|
|
|
‡2
BNE|XX5331966
|
|
996
|
|
|
‡2
DNB|1321042078
|
|
996
|
|
|
‡2
BNE|XX1093900
|
|
996
|
|
|
‡2
BNE|XX1714851
|
|
996
|
|
|
‡2
ISNI|0000000059743651
|
|
996
|
|
|
‡2
ISNI|0000000111871504
|
|
996
|
|
|
‡2
BNCHL|10000000000000000249533
|
|
996
|
|
|
‡2
DNB|1335483527
|
|
996
|
|
|
‡2
BNCHL|10000000000000000241393
|
|
996
|
|
|
‡2
ISNI|0000000078746495
|
|
996
|
|
|
‡2
SUDOC|235226416
|
|
996
|
|
|
‡2
BNE|XX826098
|
|
996
|
|
|
‡2
ISNI|0000000060317481
|
|
996
|
|
|
‡2
BAV|495_258785
|
|
996
|
|
|
‡2
LC|no2018104924
|
|
996
|
|
|
‡2
SUDOC|227515439
|
|
996
|
|
|
‡2
SUDOC|276603184
|
|
996
|
|
|
‡2
BNC|981058524830806706
|
|
996
|
|
|
‡2
BNE|XX5785631
|
|
996
|
|
|
‡2
BNCHL|10000000000000000071905
|
|
996
|
|
|
‡2
BNCHL|10000000000000000285897
|
|
996
|
|
|
‡2
BNC|981058608032106706
|
|
996
|
|
|
‡2
BNE|XX1374905
|
|
996
|
|
|
‡2
SUDOC|093668708
|
|
996
|
|
|
‡2
JPG|500271943
|
|
996
|
|
|
‡2
ISNI|0000000072375865
|
|
996
|
|
|
‡2
BNC|981060544704906706
|
|
996
|
|
|
‡2
LC|no2003013057
|
|
996
|
|
|
‡2
LC|n 2024053453
|
|
996
|
|
|
‡2
LC|ns2014001674
|
|
996
|
|
|
‡2
BNCHL|10000000000000000866586
|
|
996
|
|
|
‡2
ISNI|0000000390508512
|
|
996
|
|
|
‡2
BNE|XX825592
|
|
996
|
|
|
‡2
BNE|XX4617474
|
|
996
|
|
|
‡2
LC|no2011013757
|
|
996
|
|
|
‡2
BNE|XX4705778
|
|
996
|
|
|
‡2
NUKAT|n 2016088303
|
|
997
|
|
|
‡a
0 0 lived 0 0
‡9
1
|
